158 related articles for article (PubMed ID: 18642328)
1. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.
Kaur R; Yuan X; Lu ML; Balk SP
Prostate; 2008 Oct; 68(14):1510-6. PubMed ID: 18642328
[TBL] [Abstract][Full Text] [Related]
2. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
[TBL] [Abstract][Full Text] [Related]
4. [Cloning of human PAK6 cDNA, preparation of anti-PAK6 polyclonal antibody and PAK6 expression in prostate cancer].
Han YJ; An ZW; Yang JX; Li J; Luo RC; Zhang HQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):827-30. PubMed ID: 17584649
[TBL] [Abstract][Full Text] [Related]
5. PC-1/PrLZ contributes to malignant progression in prostate cancer.
Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG
Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733
[TBL] [Abstract][Full Text] [Related]
6. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
7. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
8. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
10. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
11. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Pang ST; Flores-Morales A; Skoog L; Chuan YC; Nordstedt G; Pousette A
Oncol Rep; 2004 Jun; 11(6):1187-92. PubMed ID: 15138554
[TBL] [Abstract][Full Text] [Related]
12. Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer.
Pinthus JH; Lu JP; Bidaisee LA; Lin H; Bryskine I; Gupta RS; Singh G
Prostate; 2007 Sep; 67(12):1330-8. PubMed ID: 17626249
[TBL] [Abstract][Full Text] [Related]
13. CaT1 expression correlates with tumor grade in prostate cancer.
Peng JB; Zhuang L; Berger UV; Adam RM; Williams BJ; Brown EM; Hediger MA; Freeman MR
Biochem Biophys Res Commun; 2001 Apr; 282(3):729-34. PubMed ID: 11401523
[TBL] [Abstract][Full Text] [Related]
14. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
16. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines.
Shaida N; Launchbury R; Boddy JL; Jones C; Campo L; Turley H; Kanga S; Banham AH; Malone PR; Harris AL; Fox SB
Prostate; 2008 Feb; 68(3):336-43. PubMed ID: 18163427
[TBL] [Abstract][Full Text] [Related]
17. Direct interaction between AR and PAK6 in androgen-stimulated PAK6 activation.
Liu X; Busby J; John C; Wei J; Yuan X; Lu ML
PLoS One; 2013; 8(10):e77367. PubMed ID: 24130878
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
20. Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Ray S; Johnston R; Campbell DC; Nugent S; McDade SS; Waugh D; Panov KI
Gene; 2013 Aug; 526(1):46-53. PubMed ID: 23608168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
